MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market…
Pharmaceuticals, Biotechnology and Life Sciences
LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market…
BioTech Breakthrough Awards The Cytek® Muse® Micro cell analyzer has been named Drug Discovery Solution of the Year in the…
First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data expected by year-end…
–First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers – – Closed a private placement of…
– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC;…
ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based…
– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million…
BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of…
Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended…
Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens…